Objective To determine the efficiency and adverse reaction of the new targeted drug—Brentuximab vedotin, in treatment of patients with relapsed or refractory Hodgkin’s lymphoma(HL). Methods Twelve patients with relapsed or refractory CD30 antigen-positive HL confirmed by pathology and immunohistochemistry treated in our hospital were enrolled in this study. All patients had received the second- or third-line chemotherapy regimens, with median 13 courses of chemotherapy. Seven patients had been treated with autologous stem cell transplantation, among which, 2 cases also underwent allogeneic stem cell transplantation because of relapse after autologous stem cell transplantation. Brentuximab vedotin was given at a dose of 1.2 to 1.8mg/kg, via intravenous injection, for a treatment phase of 21d. Patients received 2 to 16 treatment courses, with a median number of 4 courses. Results Complete remission was achieved in 2 cases(17%), partial remission in 7 cases(58%). Two out of 12 cases(17%) reached a stable condition, and 1 case died(8%). Main adverse reactions included fatigue, leukocyte reduction, fever, hair loss, elevated transaminases, nausea, peripheral neuritis, pain, etc. All of them were tolerated by this cohort of patients. Conclusion Brentuximab vedotin has good clinical efficacy in relapsed or refractory HL and has mild adverse reactions, which is tolerable for the patients.